

Publications for John Gibson

2019

Wirth, A., Prince, H., Roos, D., Gibson, J., O'Brien, P., Zannino, D., Khodr, B., Stone, J., Davis, S., Hertzberg, M. (2019). A prospective, multicentre study of involved-field radiotherapy with autologous stem cell transplantation for patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma (ALLG HDNHL04/TROG 0303). *International Journal of Radiation Oncology Biology Physics*, 103(5), 1158-1166. [More Information]

Joshua, D., Bryant, C., Dix, C., Gibson, J., Ho, P. (2019). Biology and therapy of multiple myeloma. *Medical Journal of Australia*, 210(8), 375-380. [More Information]

Talaulikar, D., Biscoe, A., Lim, J., Gibson, J., Arthur, C., Mackinlay, N., Saxena, K., Cheng, Y., Chen, V. (2019). Genetic analysis of Diffuse Large B-cell Lymphoma occurring in cases with antecedent Waldenstrom Macroglobulinaemia reveals different patterns of clonal evolution. *British Journal of Haematology*, 185(4), 767-770. [More Information]

Clucas, D., Fox, L., Wood, E., Hong, F., Gibson, J., Szer, J., Blombery, P., McQuilten, Z., Hiwase, D., Firkin, F., et al (2019). Revisiting acquired aplastic anaemia: Current concepts in diagnosis and management. *Internal Medicine Journal*, 49(2), 152-159. [More Information]

2018

Hsu, J., Bryant, C., Papadimitriou, M., Kong, B., Gasiorowski, R., Orellana, D., McGuire, H., Fazekas de St Groth, B., Joshua, D., Ho, P., Iland, H., Gibson, J., Clark, G., Fromm, P., Hart, D., et al (2018). A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission. *Onc Immunology*, 7(4), e1419114-1-e1419114-11. [More Information]

Lim, A., Curley, C., Fong, C., Bilmon, I., Beligaswatte, A., Purtill, D., Getta, B., Johnston, A., Armytage, T., Gibson, J., et al (2018). Acute myeloid leukaemia relapsing after allogeneic haematopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse. *Internal Medicine Journal*, 48(3), 276-285. [More Information]

2017

Lee, O., Horvath, N., Lee, C., Joshua, D., Ho, P., Szer, J., Quach, H., Spencer, A., Harrison, S., Mollee, P., Gibson, J., Ward, C., et al (2017). Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. *Internal Medicine Journal*, 47(8), 938-951. [More Information]

Talaulikar, D., Tam, C., Joshua, D., Ho, P., Szer, J., Quach, H., Spencer, A., Harrison, S., Mollee, P., Roberts, A., Gibson, J.,

Trotman, J., Ward, C., et al (2017). Treatment of patients with Waldenstrom macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. *Internal Medicine Journal*, 47(1), 35-49. [More Information]

2016

Bryant, C., Fromm, P., Kupresanin, F., Clark, G., Lee, K., Clarke, C., Silveira, P., Suen, H., Brown, R., Newman, E., Ho, P., Bradstock, K., Joshua, D., Hart, D., et al (2016). A CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subset. *Immunology and Cell Biology*, 94(5), 447-457. [More Information]

Suen, H., Brown, R., Yang, S., Weatherburn, C., Ho, P., Woodland, N., Nassif, N., Barbaro, P., Bryant, C., Hart, D., Gibson, J., Joshua, D. (2016). Multiple myeloma causes clonal T-cell immunosenescence: Identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. *Leukemia*, 30(8), 1716-1724. [More Information]

Ju, X., Silveira, P., Hsu, W., Elgundi, Z., Alingcastre, R., Verma, N., Fromm, P., Hsu, J., Bryant, C., Li, Z., Lo, T., Lee, K., Fazekas de St Groth, B., Larsen, S., Gibson, J., Bradstock, K., Clark, G., Hart, D., et al (2016). The Analysis of CD83 Expression on Human Immune Cells Identifies a Unique CD83+ Activated T Cell Population. *Journal of Immunology*, 197(12), 4613-4625. [More Information]

Joshua, D., Suen, H., Brown, R., Bryant, C., Ho, P., Hart, D., Gibson, J. (2016). The T cell in myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, 16(10), 537-542. [More Information]

2015

Uy, G., Costa, L., Hari, P., Zhang, M., Huang, J., Anderson, K., Bredeson, C., Callander, N., Cornell, R., Gibson, J., et al (2015). Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. *Bone Marrow Transplantation*, 50(12), 1513-1518. [More Information]

Urbano-Ispizua, A., Pavletic, S., Flowers, M., Klein, J., Zhang, M., Carreras, J., Montoto, S., Perales, M., Aljurf, M., Akpek, G., et al (2015). The Impact of Graft Versus Host Disease on Relapse Rate in Patients with Lymphoma Depends on the Histological Sub-Type and the Intensity of the Conditioning Regimen. *Biology of Blood and Marrow Transplantation*, 21(10), 1746-1753. [More Information]

Quach, H., Joshua, D., Ho, P., Szer, J., Spencer, A., Harrison, S., Mollee, P., Roberts, A., Horvath, N., Talulikar, D., Gibson, J., et al (2015). Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: Position

statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. *Internal Medicine Journal*, 45(1), 94-105. [More Information]

Quach, H., Joshua, D., Ho, P., Szer, J., Spencer, A., Harrison, S., Mollee, P., Roberts, A., Horvath, N., Talaulikar, D., Gibson, J., et al (2015). Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group. *Internal Medicine Journal*, 45(3), 335-343. [More Information]

Brown, R., McAuliffe, S., Catalano, A., Ho, P., Nassif, N., Woodland, N., Hart, D., Weatherburn, C., Yang, S., Suen, H., Joshua, D., et al (2015). Using digital polymerase chain reaction to detect minimal residual disease in myeloma by identifying FGFR3 up-regulation. *Leukemia & Lymphoma*, 56(9), 2714-2716. [More Information]

2014

Favaloro, J., Liyadipitiya, T., Brown, R., Yang, S., Suen, H., Woodland, N., Nassif, N., Hart, D., Fromm, P., Weatherburn, C., Joshua, D., et al (2014). Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma. *Leukemia & Lymphoma*, 55(12), 2893-2900. [More Information]

Favaloro, J., Brown, R., Aklilu, E., Yang, S., Suen, H., Hart, D., Fromm, P., Gibson, J., Khoo, L., Ho, P., Joshua, D. (2014). Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. *Leukemia & Lymphoma*, 55(5), 1090-1098. [More Information]

Wright, C., Velickovic, Z., Brown, R., Larsen, S., Macpherson, J., Gibson, J., Rasko, J. (2014). Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products. *Pathology*, 46(3), 177-183. [More Information]

2013

Talbot, J., Martin, P., Johnson, L., Beatty, J., Sutton, D., Halliday, C., Gibson, J., Kiddell, L., Steiner, J., Ujvari, B., Barrs, V. (2013). A molecular approach to identification of species causing sinonasal aspergillosis. *The Australian Society for Microbiology, Annual Scientific Meeting*.

Hamadani, M., Saber, W., Ahn, K., Carreras, J., Cairo, M., Fenske, T., Gale, R., Gibson, J., Hale, G., Hari, P., et al (2013). Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. *Biology of Blood and Marrow Transplantation*, 19(4), 625-631. [More Information]

Maziarz, R., Wang, Z., Zhang, M., Bolwell, B., Chen, A., Fenske, T., Freytes, C., Gale, R., Gibson, J., Hayes-Lattin, B., et al (2013). Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement. *British Journal of Haematology*, 162(5), 648-656. [More Information]

Hamadani, M., Saber, W., Ahn, K., Carreras, J., Cairo, M., Fenske, T., Gale, R., Gibson, J., Hale, G., Hari, P., et al (2013). Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. *Biology of Blood and Marrow Transplantation*, 19(5), 746-753. [More Information]

Gibson, J., Iland, H., Larsen, S., Brown, C., Joshua, D. (2013). Leukaemias into the 21st century - part 2: the chronic leukaemias. *Internal Medicine Journal*, 43(5), 484-494. [More Information]

Bryant, C., Suen, H., Brown, R., Yang, S., Favaloro, J., Aklilu, E., Gibson, J., Ho, P., Iland, H., Fromm, P., Hart, D., Joshua, D., et al (2013). Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. *Blood Cancer Journal*, 3, 1-7. [More Information]

Gasiorowski, R., Gibson, J., Watson, G., Trotman, J., Larsen, S. (2013). Rapidly fatal post-allogeneic stem cell transplant lymphoproliferative disorder presenting with skin and bone marrow involvement. *Pathology*, 45(1), 81-83. [More Information]

Michaelis, L., Saad, A., Zhong, X., Le-Rademacher, J., Freytes, C., Marks, D., Lazarus, H., Bird, J., Holmberg, L., Kamble, R., et al (2013). Salvage second hematopoietic cell transplantation in myeloma. *Biology of Blood and Marrow Transplantation*, 19(5), 760-766. [More Information]

Ahmed, R., King, J., Gibson, J., Buckland, M., Gupta, R., Gonzales, M., Halmagyi, M. (2013). Spinal Leptomeningeal Lymphoma presenting as Pseudotumor Syndrome. *Journal of Neuro-Ophthalmology*, 33(1), 13-16. [More Information]

2012

Brown, R., Karieshma, K., Favaloro, J., Yang, S., Joy Ho, P., Gibson, J., Fromm, P., Suen, H., Woodland, N., Nassif, N., Hart, D., Joshua, D. (2012). CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells T cells and are associated with poor prognosis. *Blood*, 120(10), 2055-2063. [More Information]

Chohan, G., Barnett, Y., Gibson, J., Reddel, S., Barnett, M. (2012). Langerhans cell histiocytosis with refractory central nervous system involvement responsive to infliximab. *Journal of Neurology, Neurosurgery and Psychiatry*, 83(5), 573-575. [More Information]

Brown, C., Larsen, S., Iland, H., Joshua, D., Gibson, J. (2012). Leukaemias into the 21st century: part 1: the acute leukaemias. *Internal Medicine Journal*, 42(11), 1179-1186. [More Information]

Gibson, J., Weatherburn, C. (2012). Polycythaemia. *Medical Observer*, 21st August 2012.

Ho, P., Brown, R., Spencer, A., Jeffels, M., Daniher, D., Gibson, J., Joshua, D. (2012). Thalidomide consolidation

improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial. *Leukemia & Lymphoma*, 53(9), 1728-1734. [More Information]

Brown, R., Suen, H., Favaloro, J., Yang, S., Ho, P., Gibson, J., Joshua, D. (2012). Trogocytosis generates acquired regulatory T cells adding further complexity to the dysfunctional immune response in multiple myeloma. *Onc Immunology*, 1(9), 1658-1660. [More Information]

2011

Nivison-Smith, I., Dodds, A., Doocey, R., Ganly, P., Gibson, J., Ma, D., Simpson, J., Szer, J., Bradstock, K., Bradstock, K. (2011). Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: factors associated with improved survival outcome. *Leukemia & Lymphoma*, 52(9), 1727-1735. [More Information]

Passweg, J., Zhang, M., Rocha, V., Kan, F., Champlin, R., Isola, L., Gee, A., Gibson, J., Laughlin, M., Lazarus, H., et al (2011). Donor Characteristics Affecting Graft Failure, Graft-versus-Host Disease, and Survival after Unrelated Donor Transplantation with Reduced-Intensity Conditioning for Hematologic Malignancies. *Biology of Blood and Marrow Transplantation*, 17(12), 1869-1873. [More Information]

Vogl, D., Wang, T., Perez, W., Stadtmauer, E., Heitjan, D., Lazarus, H., Kyle, R., Kamble, R., Weisdorf, D., Roy, V., Gibson, J., et al (2011). Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. *Biology of Blood and Marrow Transplantation*, 17(12), 1765-1774. [More Information]

Khoo, T., Vangsted, A., Joshua, D., Gibson, J. (2011). Interferon-Alpha in the Treatment of Multiple Myeloma. *Current Drug Targets (online)*, 12(3), 437-446. [More Information]

Brown, R., Langshaw, M., Uhr, E., Gibson, J., Joshua, D. (2011). The impact of mandatory fortification of flour with folic acid on the blood folate levels of an Australian population. *Medical Journal of Australia*, 194(2), 65-67. [More Information]

2010

Suryani, S., Fulcher, D., Nanan, B., Nanan, R., Wong, M., Shaw, P., Gibson, J., Williams, A., Tangye, S. (2010). Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells. *Blood*, 115(3), 519-529. [More Information]

Reece, D., Vesole, D., Shrestha, S., Zhang, M., Perez, W., Dispenzieri, A., Milone, G., Abidi, M., Atkins, H., Bashey, A., Gibson, J., et al (2010). Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study.

Clinical Lymphoma, Myeloma and Leukemia, 10(6), 458-463. [More Information]

Hari, P., Majhail, N., Zhang, M., Hassebroek, A., Siddiqui, F., Ballen, K., Bashey, A., Bird, J., Freytes, C., Gibson, J., et al (2010). Race and Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. *Biology of Blood and Marrow Transplantation*, 16(3), 395-402. [More Information]

2009

Brown, R., Spencer, A., Ho, J., Kennedy, N., Kabani, K., Yang, S., Sze, D., Aklilu, E., Gibson, J., Joshua, D. (2009). Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. *Leukemia & Lymphoma*, 50(11), 1860-1864. [More Information]

Devetten, M., Hari, P., Carreras, J., Logan, B., van Besien, K., Bredeson, C., Freytes, C., Gale, R., Gibson, J., Giralt, S., et al (2009). Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. *Biology of Blood and Marrow Transplantation*, 15(1), 109-117. [More Information]

2008

Kumar, S., Perez, W., Zhang, M., Ballen, K., Bashey, A., To, L., Bredeson, C., Cairo, M., Elfenbein, G., Freytes, C., et al (2008). Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation. *Biology of Blood and Marrow Transplantation*, 14(10), 1134-1140. [More Information]

Bashey, A., Perez, W., Zhang, M., Anderson, K., Ballen, K., Berenson, J., To, L., Fonseca, R., Freytes, C., Gale, R., et al (2008). Comparison of twin and autologous transplants for multiple myeloma. *Biology of Blood and Marrow Transplantation*, 14(10), 1118-1124. [More Information]

Joshua, D., Brown, R., Gibson, J. (2008). Regulatory T cells and Multiple Myeloma. *Clinical Lymphoma & Myeloma*, 8(5), 283-286. [More Information]

Burgess, P., Robin, H., Langshaw, M., Kershaw, G., Pathiraja, R., Yuen, S., Coad, C., Xiros, N., Mansy, G., Coleman, R., Gibson, J., Joshua, D., et al (2008). Rule based processing of the CD4000, CD3200 and CD Sapphire analyser output using the Cerner Discern Expert Module. *International Journal of Laboratory Hematology*, 31(6), 603-614. [More Information]

2007

Grigg, A., Gibson, J., Bardy, P., Reynolds, J., Shuttleworth, P., Koelmeyer, R., Szer, J., Roberts, A., To, L., Kennedy, G., Bradstock, K. (2007). A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. *Biology of Blood and Marrow Transplantation*, 13(5), 560-567. [More Information]

<http://dx.doi.org/10.1016/j.bbmt.2006.12.449>>[More Information]

Loh, Y., Mo, S., Brown, R., Yamagishi, T., Yang, S., Joshua, D., Ho, P., Gibson, J., Roufogalis, B., Sze, D. (2007). Characteristics of 'side population' as the putative cancer stem cells in myeloma: Cell growth and differentiation capability. *Molecular Cancer Therapeutics*, 6(12), 3365s-3366s.

Sanders, J., Crawford, B., Gibson, J., Ho, P., Iland, H., Joshua, D. (2007). Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS). *International Journal of Laboratory Hematology*, 29(5), 395-397. [More Information]

Ling, S., Campbell, L., Ho, P., Gibson, J., Joshua, D. (2007). Molecular Biology, Pathology, and Cytogenetics. In Mikkael A. Sekeres, Matt E. Kalaycio, Brian J. Bolwell (Eds.), *Clinical Malignant Haematology*, (pp. 847-857). United States: McGraw Hill.

Feyler, S., Prince, H., Pearce, R., Towson, K., Nivison-Smith, I., Schey, S., Gibson, J., Patton, N., Bradstock, K., Marks, D., et al (2007). The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. *Bone Marrow Transplantation*, 40(5), 443-450. [More Information]

Joshua, D., Brown, R., Sze, D., Hodges, P., Gibson, J. (2007). The role of T-cells in myeloma. *XIth International Myeloma Workshop & IVth International Workshop on Waldenstrom's Macroglobulinemia*, Italy: Fondazione Ferrata Storti.

2006

Gibson, J., Anagnostopoulos, A., Hari, P., Párez, W., Ballen, K., Bashey, A., Bredeson, C., Freytes, C., Gale, R., Gertz, M., et al (2006). Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. *Biology of Blood and Marrow Transplantation*, 12(8), 845-854. [More Information]

Sze, D., Brown, R., Yang, S., Ho, P., Gibson, J., Joshua, D. (2006). The use of thalidomide in myeloma therapy as an effective anticancer drug. *Current Cancer Drug Targets*, 6(4), 325-331. [More Information]

Ling, S., Joshua, D., Gibson, J., Young, G., Iland, H., Watson, G., Ho, P. (2006). Transformation and Progression of Waldenstrom's Macroglobulinemia Following Cladribine Therapy in Two Cases: Natural Evolution or Iatrogenic Causation? *American Journal Of Hematology*, 81(2), 110-114. [More Information]

2005

Gibson, J., Joshua, D., Ho, P., Campbell, L., Ling, S. (2005). Multiple Myeloma: molecular biology, Pathology and Cytogenetics. In Susan Hallam, Ian Cross, Michael Thaut (Eds.), *Oxford Handbook of Music Psychology*. Oxford, UK: Oxford University Press.

Gibson, J., Prosser, I., Spencer, A., Horvath, N., Prince, R., Herrmann, R., Bashford, J., Joske, D., Grigg, A., McKendrick, J., et al (2005). Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. *Bone Marrow Transplantation*, 35(10), 971-7. [More Information]

<http://dx.doi.org/10.1038/sj.bmt.1704946>>[More Information]

2004

Brown, R., Murray, A., Pope, B., Sze, D., Gibson, J., Ho, P., Joshua, D. (2004). B7+ T Cells In Myeloma: An Acquired Marker Of Prior Chronic Antigen Presentation. *Leukemia and Lymphoma*, 45(2), 363-371. [More Information]

Brown, R., Murray, A., Pope, B., Sze, D., Gibson, J., Ho, P., Hart, D., Joshua, D. (2004). Either Interleukin-12 Or Interferon- β Can Correct The Dendritic Cell Defect Induced By Transforming Growth Factor β_1 In Patients With Myeloma. *British Journal of Haematology*, 125(2), 743-748. [More Information]

Gibson, J., Ho, P., Joshua, D. (2004). Evolving Transplant Options For Multiple Myeloma: Autologous And Nonmyeloablative Allogeneic. *Transplantation Proceedings*, 36(8), 2501-2503. [More Information]

Mollee, P., Arthur, C., Hughes, T., Januszewicz, H., Grigg, A., Bradstock, K., Wolf, M., Gibson, J., Schwarzer, A., Spencer, A., et al (2004). Interferon-Alpha-2B And Oral Cytarabine Ocfosfate For Newly Diagnosed Chronic Myeloid Leukaemia. *Annals of Oncology*, 15(12), 1810-1815. [More Information]

Horvath, N., Hahn, U., Joshua, D., Dyson, P., Gibson, J., Stevens, J., Rawling, T., Barrow, L., Brown, R., Stephens, S., et al (2004). Long-Term Follow Up Of Sequential Mobilisation And Autologous Transplantation With Cd34-Selected Cells In Multiple Myeloma: A Multimodality Approach. *Internal Medicine Journal*, 34, 167-175. [More Information]

Gibson, J., Ho, P., Joshua, D. (2004). Low-Grade Lymphoma: The Optimal Timing. *Transplantation Proceedings*, 36(7), 1995-1998. [More Information]

Szer, J., Durrant, S., Schwarzer, A., Bradstock, K., Gibson, J., Arthur, C., To, L., Hughes, T., Raunow, H. (2004). Oral Versus Intravenous Ganciclovir For The Prophylaxis Of Cytomegalovirus Disease After Allogeneic Bone Marrow Transplantation. *Internal Medicine Journal*, 34(3), 98-101. [More Information]

Joshua, D., Gibson, J., Brown, R., Ho, P. (2004). The Immune System In Myeloma. In Gosta Garton, Brian Durie, Diana Samson (Eds.), *Multiple myeloma and related disorders*, (pp. 29-46). UK: Hodder Arnold.

Ho, P., Gibson, J., Joshua, D. (2004). Treatment Of Multiple Myeloma: Current Management And New Approaches. *American Journal of Cancer*, 3(1), 47-66. [More Information]

2003

Sze, D., Brown, R., Yuen, E., Gibson, J., Ho, P., Raitakari, M., Basten, A., Joshua, D., Fazekas de St Groth, B. (2003). Clonal Cytotoxic T Cells in Myeloma. *Leukemia and Lymphoma*, 44(10), 1667-1674. [More Information]

<http://dx.doi.org/10.1080/1042819031000097438>>[More Information]

Barrow, L., Brown, R., Murray, A., Sze, D., POPE, B., Gibson, J., Hart, D., Joshua, D. (2003). CMRF44+ Dendritic Cells from Peripheral Blood Stem Cell Harvests of Patients with Myeloma as Potential Cellular Vectors for Idiotype Vaccination. *Leukemia and Lymphoma*, 44(12), 2117-2122. <<http://dx.doi.org/10.1080/1042819031000123401>>[More Information]

Gibson, J., et al (2003). Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. *Blood*, 102(10), 3521-3529. <<http://dx.doi.org/10.1182/blood-2003-04-1205>>[More Information]

Sze, D., Brown, R., Yang, S., Gibson, J., Ho, P., Fazekas de St Groth, B., Basten, A., Joshua, D. (2003). Prediction of high affinity class I-restricted multiple myeloma idiotype peptide epitopes. *Leukemia and Lymphoma*, 44(9), 1557-1568. <<http://dx.doi.org/10.1080/1042819031000097429>>[More Information]

Raitakari, M., Brown, R., Gibson, J., Joshua, D. (2003). T cells in myeloma. *Hematological Oncology*, 21(1), 33-42. <<http://dx.doi.org/10.1002/hon.704>>[More Information]

2002

Ho, P., Gibson, J., Joshua, D., Campbell, L., Brown, R. (2002). The biology and cytogenetics of multiple myeloma. *Reviews in Clinical and Experimental Hematology*, 6(3), 276-300. <<http://dx.doi.org/10.1046/j.1468-0734.2002.00081.x>>[More Information]

2001

Nivison-Smith, I., Bradstock, K., Szer, J., Durrant, S., Dodds, A., Hermann, R., Schwarzer, A., Gibson, J., To, L., Arthur, C. (2001). Allogeneic haemopoietic cell transplants in Australia, 1996--a multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow. *Bone Marrow Transplantation*, 28(1), 21-27.

Sze, D., Giesajtis, G., Brown, R., Raitakari, M., Gibson, J., Ho, P., Baxter, A., Fazekas de St Groth, B., Basten, A., Joshua, D. (2001). Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+Cd57+CD28- compartment. *Blood*, 98(9), 2817-2827.

Brown, R., POPE, B., Murray, A., Esdale, W., Sze, D., Gibson, J., Ho, J., Hart, D., Joshua, D. (2001). Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-B1 and interleukin-10. *Blood*, 98(10), 2992-2998.

Ho, P., Basten, A., Gibson, J., Joshua, D., Brown, R., Pelka, G. (2001). Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival. *Blood*, 97, 490-495.